This study aims to evaluate the adverse effects, oxidative stress, and genotoxic potential of two cinnamic acid derivatives (LQMs) encapsulated in PLGA nanoparticles (NPs LQMs-PLGA) through in silico and in vivo approaches using Wistar rats. Acute toxicity will be assessed using the Up-and-Down Procedure (OECD TG 425), while repeated-dose toxicity will be evaluated in a 28-day study (OECD TG 407). Clinical observations, biochemical parameters, hematological profiles, and histopathological examinations will be performed. Oxidative stress will be determined by quantifying thiobarbituric acid reactive species (TBARS), reduced glutathione (GSH), and catalase (CAT) activity in liver and kidney tissues. Genotoxicity will be assessed using the mammalian erythrocyte micronucleus test (OECD TG 474) at two time points: 48 hours post-treatment and at the end of the treatment period (day 28). The results will establish the median lethal dose (LD50), the no-observed-adverse-effect level (NOAEL), and the overall toxicological profile of these formulations as potential anticancer therapeutics.
Maria Guadalupe Prado Ochoa (Thu,) studied this question.